Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06956157 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NAC for Treatment-Resistant OCD and Other Related Disorders

StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion date: Aug 13, 2025 to Nov 13, 2025v4
  2. Primary endpoints: 3 to 2v3 Show 5 more changesShow less
    • Interventions: N-Acetylcysteine Tablets (Drug) to N-Acetylcysteine Tablets (Drug), Placebo Oral Tablet (Drug)
    • Eligibility criteria expanded, about 106 words
    • Secondary endpoints: 1 to 2
    • Study description expanded, about 201 words
    • Study title revised
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized, double-blind, placebo-controlled study investigating N-acetylcysteine (NAC) as an augmentation therapy for individuals with treatment-resistant obsessive-compulsive disorder (TR-OCD), studied within a broader cohort of treatment-resistant Obsessive-Compulsive and Related Disorders (OCRDs). The study's primary aim is to investigate the neurobiological mechanism by which NAC improves inhibitory control deficits in TR-OCD. This is achieved by using Magnetic Resonance Spectroscopy (MRS) to measure changes in thalamic glutamatergic metabolism. A secondary aim is to assess the clinical efficacy of this augmentation strategy on symptom severity. The central hypothesis is that improvements in inhibitory control are mediated by NAC-induced changes in brain glutamate levels.
Trial Details
NCT Number NCT06956157
Lead Sponsor Guangdong Provincial People's Hospital
Conditions
(from sponsor)		 Obsessive Compulsive Disorder (OCD)
Related terms Obsessive-Compulsive Disorder
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov